Increasing evidence suggests that Kv1.3 channels could represent a target of interest for the development of novel therapeutics for neurodegenerative diseases (Rangaraju et al., 2009; Chen et al., 2017; Maezawa et al., 2018; Sarkar et al., 2020; Cojocaru et al., 2021), epilepsy (Zhang et al., 2022), and glioma (Grimaldi et al., 2018). The gene discussed is KCNA3; the disease is central nervous system cancer.